Semaglutide (Rybelsus)

Peptide

Also known as NN9924

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
EU
  • Rybelsus (oral semaglutide): insufficiently controlled type 2 diabetes mellitus in adults
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (20)
Type 2 Diabetes
NCT06083675 · Novo Nordisk A/S
2024-01-26 – 2027-05-28 · Diabetes Mellitus, Type 2
What this study did
NCT04596631 · Novo Nordisk A/S
2020-11-02 – 2026-02-03 · Diabetes Mellitus, Type 2
What this study did
NCT05444153 · Novo Nordisk A/S
2022-10-06 – 2025-08-29 · Diabetes Mellitus, Type 2
What this study did
NCT04707469 · Novo Nordisk A/S
2021-01-15 – 2023-03-08 · Diabetes Mellitus, Type 2
What this study did
NCT04109547 · Novo Nordisk A/S
2019-10-01 – 2021-10-27 · Diabetes Mellitus, Type 2
What this study did
NCT04017832 · Novo Nordisk A/S
2019-07-29 – 2021-10-27 · Diabetes Mellitus, Type 2
What this study did
NCT02849080 · Novo Nordisk A/S
2016-09-20 – 2019-03-27 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03018028 · Novo Nordisk A/S
2017-01-10 – 2018-08-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03015220 · Novo Nordisk A/S
2017-01-10 – 2018-07-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04777409 · Novo Nordisk A/S
2021-05-18 – 2026-01-30 · Early Alzheimer´s Disease
What this study did
NCT04777396 · Novo Nordisk A/S
2021-05-18 – 2026-01-30 · Early Alzheimer's Disease
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03919929 · University of Colorado, Denver
2019-05-03 – 2023-10-03 · PCOS, Adolescent Obesity, NAFLD
What this study did
Phase 2 (9)
Type 2 Diabetes
NCT06050577 · Odense University Hospital
2024-06-07 – 2027-03-15 · Type 2 Diabetes, Osteopenia
What this study did
NCT01923181 · Novo Nordisk A/S
2013-12-02 – 2014-12-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07135245 · Rune Skovgaard Rasmussen
2026-01-01 – 2031-09-30 · Alzheimer Disease (AD)
What this study did
NCT07923630 · The University of Texas Health Science Center at San Antonio
2027-01 – 2031-02 · Aging, Functional Decline
What this study did
NCT07221214 · Vanderbilt University Medical Center
2026-04-17 – 2030-01-31 · HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention
What this study did
NCT07200622 · Imperial College London
2025-09-25 – 2028-12-31 · Alzheimer Disease
What this study did
NCT07179120 · First Affiliated Hospital of Wenzhou Medical University
2026-05-01 – 2027-01-02 · Obesity-related Male Infertility
What this study did
NCT07819227 · University Medical Center Groningen
2025-02-11 – 2026-08-31 · Chronic Kidney Disease
What this study did
NCT05892432 · University of Colorado, Denver
2024-01-11 – 2025-11-15 · Alcohol Use Disorder
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07642635 · Vanderbilt University Medical Center
2026-12 – 2030-12 · Duchenne Muscular Dystrophy (DMD)
What this study did
Phase 1 (23)
Type 2 Diabetes
NCT05227196 · Novo Nordisk A/S
2022-02-04 – 2023-08-08 · Healthy Volunteers, Type 2 Diabetes
What this study did
NCT04817644 · Novo Nordisk A/S
2021-09-10 – 2023-07-03 · Diabetes Mellitus, Type 2
What this study did
NCT04524832 · Novo Nordisk A/S
2020-09-29 – 2022-02-25 · Diabetes Mellitus, Type 2
What this study did
NCT04513704 · Novo Nordisk A/S
2020-08-28 – 2021-05-26 · Healthy Volunteers Type 2 Diabetes
What this study did
NCT04016974 · Novo Nordisk A/S
2019-10-08 – 2021-02-26 · Healthy Volunteers, Diabetes Mellitus, Type 2
What this study did
NCT04109508 · Novo Nordisk A/S
2019-10-02 – 2021-01-27 · Healthy Volunteers, Type 2 Diabetes
What this study did
NCT04097600 · Novo Nordisk A/S
2019-09-30 – 2021-01-20 · Healthy Volunteers, Type 2 Diabetes
What this study did
NCT02877355 · Novo Nordisk A/S
2016-08-22 – 2017-11-24 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02016911 · Novo Nordisk A/S
2013-12-12 – 2015-01-12 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT02161588 · Novo Nordisk A/S
2014-06 – 2014-11 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT02014259 · Novo Nordisk A/S
2013-12-11 – 2014-10-24 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
NCT01037582 · Novo Nordisk A/S
2009-12-17 – 2010-05-07 · Diabetes, Diabetes Mellitus, Type 2, Healthy
What this study did
Other / comorbidity
NCT06446531 · The University of Texas Health Science Center at San Antonio
2024-09-11 – 2027-07 · Pre-Diabetes, Weight, Body, Cardiovascular Diseases
What this study did
NCT06338553 · Vanderbilt University Medical Center
2024-06-12 – 2027-03 · Type 1 Diabetes
What this study did
NCT05784402 · Novo Nordisk A/S
2023-03-16 – 2024-03-29 · Healthy Participants
What this study did
NCT03010475 · Novo Nordisk A/S
2017-01-05 – 2017-08-09 · Diabetes, Healthy
What this study did
NCT02249871 · Novo Nordisk A/S
2014-09-24 – 2015-04-01 · Diabetes, Healthy
What this study did
NCT02249910 · Novo Nordisk A/S
2014-09-18 – 2015-03-06 · Diabetes, Healthy
What this study did
NCT02172313 · Novo Nordisk A/S
2014-06 – 2014-10 · Diabetes, Healthy
What this study did
NCT02070510 · Novo Nordisk A/S
2014-02-27 – 2014-08-20 · Diabetes, Healthy
What this study did
Phase 4 (12)
Atherosclerotic Cardiovascular Disease
NCT07254572 · National Institute of Cardiology, Warsaw, Poland
2025-07-10 – 2029-08-01 · Coronary Artery Disease, PreDiabetes
What this study did
Type 2 Diabetes
NCT05441267 · University of Oxford
2023-03-13 – 2048-08-17 · Diabetes Mellitus, Type 2
What this study did
NCT06613854 · University Medical Centre Ljubljana
2024-10-01 – 2027-12 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06003153 · Massachusetts General Hospital
2024-03-12 – 2027-05-31 · Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
What this study did
NCT06557811 · University of Sao Paulo General Hospital
2024-09-01 – 2026-09-01 · Diabetic Patients, Acute Myocardial Infarction
What this study did
NCT05035082 · Novo Nordisk A/S
2021-09-01 – 2025-06-18 · Diabetes Mellitus, Type 2
What this study did
NCT04938388 · Sansum Diabetes Research Institute
2022-01-29 – 2023-02-16 · Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
What this study did
Other / comorbidity
NCT06792422 · Glostrup University Hospital, Copenhagen
2025-01 – 2028-12 · Primary Open Angle Glaucoma (POAG), Open-Angle Glaucoma, Glaucoma
What this study did
NCT05702931 · Copenhagen University Hospital, Rigshospitalet
2024-09-19 – 2027-12 · Hyperglycemia, Renal Transplant Complication Primary Non-Function, Diabetes
What this study did
NCT07401992 · Hospital Universitario Dr. Jose E. Gonzalez
2026-01-15 – 2027-02-28 · Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2
What this study did
NCT05813249 · Zagazig University
2023-02-15 – 2024-04-01 · Non-alcoholic Fatty Liver Disease
What this study did
NCT04865744 · University of Tartu
2021-05-19 – 2021-09-30 · Healthy
What this study did
Early phase / not applicable (5)
Atherosclerotic Cardiovascular Disease
NCT05147896 · University Medical Centre Ljubljana
2022-05-01 – 2023-12-01 · Diabetes Mellitus, Type 2, Atherosclerosis
What this study did
Other / comorbidity
NCT07391267 · Institute of Liver and Biliary Sciences, India
2026-05-25 – 2028-12-31 · Chronic Kidney Diseases, MAFLD
What this study did
NCT06318442 · Imperial College London
2024-05-15 – 2027-06-01 · Steroid-Induced Diabetes, Steroid Induced Hyperglycemia
What this study did
NCT05340868 · Medical University of Bialystok
2022-09-01 – 2025-12-31 · PreDiabetes, Prediabetic State, Obesity
What this study did
NCT06060392 · Medanta, The Medicity, India
2023-10-30 – 2025-11-01 · Liver Transplant; Complications, Diabete Mellitus
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Type 2 Diabetes
NCT07487103 · Qilu Pharmaceutical Co., Ltd.
2026-05-01 – 2027-05 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07297589 · Instituto Mexicano del Seguro Social
2025-12-30 – 2027-03 · STEMI - ST Elevation Myocardial Infarction, Epicardial Fat
What this study did
NCT07295223 · Instituto Mexicano del Seguro Social
2025-12-30 – 2026-10-30 · Acute Myocardial Infarction With ST Elevation
What this study did
Phase 2 (2)
Type 2 Diabetes
NCT07801820 · Shanghai Minwei Biotechnology Co., Ltd
2026-06-23 – 2027-03 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT05579977 · Pfizer
2022-10-27 – 2023-09-22 · Diabetes Mellitus, Obesity
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06827002 · University of Yaounde 1
2023-03-29 – 2026-08 · Obesity and Overweight, Appetite Regulation
What this study did
Phase 1 (1)

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Semaglutide (Rybelsus): this drugApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Saxenda)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Wegovy Tablets)
Approved(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MDR-001
Phase 3(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
Zovaglutide
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication
BW-20829Phase 2RNA / oligonucleotideLipoprotein(a) [Lp(a)] production pathwaynot yet gradedNo reviewed efficacy summary in this indication
CNIC-Ferrer Polypill (Trinomia)Phase 2Small moleculeMulti-mechanism secondary-prevention polypillPartial signalNo reviewed efficacy summary in this indication
DNV001Phase 2RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3Weak signalNo reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
TE-8105
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
ZT006
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 1/2Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Weak signal
NCT03381287: Day 28, 2000 mg/day (highest dose) vs placebo: total cholesterol -8.2% (P=0.0004); LDL-C -10.4% (P=0.0006). Lower doses (500 mg, 1000 mg) did not reach significance.
BMF-650
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
DehydraTECH-CBD / Semaglutide
Phase 1(overall)
CombinationOral peptide delivery platform, GLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
IBI3032
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Liraglutide (HUC2-676)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08642534
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08656795
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (DWRX5003)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 82 furthest-along competitors are listed; 57 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Semaglutide (Rybelsus) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (9)
January 2027 (1)
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2027-01-15 · NCT06050577 · CT.gov ↗
What to watch
February 2027 (1)
Phase 4Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2Recruiting
Est. primary completion 2027-02-28 · NCT07401992 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Type 1 DiabetesRecruiting
Est. primary completion 2027-03 · NCT06338553 · CT.gov ↗
What to watch
May 2027 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-05-31 · NCT06003153 · CT.gov ↗
What to watch
June 2027 (1)
Early phase / not applicableSteroid-Induced Diabetes, Steroid Induced HyperglycemiaRecruiting
Est. primary completion 2027-06-01 · NCT06318442 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Pre-Diabetes, Weight, Body, Cardiovascular DiseasesRecruiting
Est. primary completion 2027-07 · NCT06446531 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-09 · NCT06613854 · CT.gov ↗
What to watch
December 2027 (2)
Phase 4Hyperglycemia, Renal Transplant Complication Primary Non-Function, DiabetesRecruiting
Est. primary completion 2027-12 · NCT05702931 · CT.gov ↗
What to watch
Phase 2Alzheimer DiseaseNot yet recruiting
Est. primary completion 2027-12-31 · NCT07200622 · CT.gov ↗
What to watch
2028 (3)
August 2028 (2)
Phase 4Primary Open Angle Glaucoma (POAG), Open-Angle Glaucoma, GlaucomaRecruiting
Est. primary completion 2028-08 · NCT06792422 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesActive not recruiting
Est. primary completion 2028-08-17 · NCT05441267 · CT.gov ↗
What to watch
December 2028 (1)
Early phase / not applicableChronic Kidney Diseases, MAFLDRecruiting
Est. primary completion 2028-12-31 · NCT07391267 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2029-08-01 · NCT07254572 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease PreventionRecruiting
Est. primary completion 2029-10-31 · NCT07221214 · CT.gov ↗
What to watch
2030 (3)
September 2030 (2)
Phase 1/2Duchenne Muscular Dystrophy (DMD)Recruiting
Est. primary completion 2030-09 · NCT07642635 · CT.gov ↗
What to watch
Phase 2Alzheimer Disease (AD)Not yet recruiting
Est. primary completion 2030-09-30 · NCT07135245 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Aging, Functional DeclineNot yet recruiting
Est. primary completion 2030-12 · NCT07923630 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 October 2025ApprovalFDA approves Rybelsus for CV risk reduction in type 2 diabetes
US, FDA · Source ↗
15 September 2025ApprovalEU approval of Rybelsus label update with SOUL cardiovascular benefits
EU, EMA · Source ↗